Glide Pharma Completes £14M Funding

Glide Pharma, an Oxford, United Kingdom-based pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, completed a £14.0m (approximately $21.4m) funding.

The round was led by funds managed by Invesco Perpetual, with participation from existing investors (Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT).

The company intends to use the capital to scale up the manufacturing process for its proprietary Glide SDI solid dose injector system, including both the drug product and device as well as to develop its in-house programmes, which include epinephrine and parathyroid hormone.

Led by Ian Smith, CEO, Glide Pharma develops Glide SDI®, a needle-free delivery system that uses a spring mechanism to administer a tiny solid dosage below the patient’s skin, where it dissolves and releases the pharmaceutical.



Join the discussion